Dr. Philip Toleikis reports
SERNOVA RENEWS FRONTIER FLEX FOR CANADIAN INVESTOR RELATIONS AND MARKETING
Sernova Corp. has renewed the engagement of Frontier Flex, an investor relations (IR) and marketing group based in Toronto, Ont., Canada, to provide Canadian IR and strategic marketing services.
Sernova's president and chief executive officer, Dr. Philip Toleikis, commented, "Frontier remains an integral part of the communications strategy Sernova is implementing to increase Sernova's visibility and help investors and shareholders stay well informed as we advance our clinical programs, including our U.S. diabetes phase 1/2 clinical study."
Through its established network of financial industry professionals, marketing service providers and outreach programs, FronTier will assist the corporation by increasing market awareness for the corporation using a number of financial market communications initiatives, including: facilitating in-person introductions for the corporation with institutional and retail brokers in Toronto and other financial capitals; and through media distribution on national television, radio and multiple on-line channels.
Under the terms of the engagement, FronTier has been retained for a 12-month period for aggregate remuneration of $100,000 plus expenses. The agreement with Frontier Flex is subject to the approval of the TSX Venture Exchange.
In other news, Sernova has granted 6.98 million stock options to certain officers, employees and consultants of the company, each such option being exercisable into one common share at a price of 21 cents per share for periods ranging from three to 10 years. The company has also granted 3,120,167 deferred share units to its directors.
About Sernova Corp.
Sernova is developing regenerative medicine therapeutic technologies using a medical device and immune-protected therapeutic cells to improve the treatment and quality of life of people with chronic metabolic diseases, such as insulin-dependent diabetes, blood disorders, including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body.
We seek Safe Harbor.
© 2020 Canjex Publishing Ltd. All rights reserved.